DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations

Information source: Texas Tech University Health Sciences Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Obesity; Pharmacokinetics; MRSA; Tuberculosis; PCP

Intervention: Sulfamethoxazole/trimethoprim (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Texas Tech University Health Sciences Center

Official(s) and/or principal investigator(s):
Ronald Hall, PharmD, MSCS, Principal Investigator, Affiliation: Texas Tech UHSC


This study will find how weight affects the dosing of a drug called sulfamethoxazole and trimethoprim. Currently, the amount of sulfamethoxazole and trimethoprim a patient receives is the same regardless of the patient's weight. All sulfamethoxazole and trimethoprim (Trade name is Bactrim or Septra) medication that you will receive in this study will be referred to as study medication within this informed consent form. This drug is a combination of two antibiotics, sulfamethoxazole and trimethoprim, which belongs to a class of medication known as "sulfones" and is approved by the US Food and Drug Administration (FDA) for the treatment of a wide variety of bacterial infections such as ear infections, urinary tract infections, bronchitis, traveler's diarrhea, and Pneumocystis carinii pneumonia. Sulfamethoxazole and trimethoprim is given orally.

Clinical Details

Official title: Population Pharmacokinetic Analysis of Sulfamethoxazole and Trimethoprim in Normal Weight, Overweight, and Obese Volunteers

Study design: Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Serum clearance


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Male and female subjects, age >18 years, of all racial and ethnic origins.

- We are recruiting 12 normal or underweight (BMI <25kg/m2), 12 overweight or obese

(BMI 25-40 kg/m2), and 12 extremely obese (BMI > 40 kg/m2) for this study. This index is calculated using the volunteer's height and weight (Formula: weight (lb) / [height (in)]2 x 703). Half of each group will be male; the other half will be female. Exclusion Criteria:

- Pregnant or nursing or unwilling to use a reliable contraception method during the

study. The effects of sulfamethoxazole and trimethoprim on pregnancy are unknown. In addition, the metabolic changes that accompany pregnancy may alter the concentration-time profile of sulfamethoxazole and trimethoprim, so that the pregnancy and post-partum state would be a confounding variable.

- Abnormal liver function tests: transaminases>10 times upper limit of normal, Alkaline

phosphatase>5 times upper limit of normal, total bilirubin>5 times upper limit of normal.

- History of allergies to sulfones, sulfonamides or trimethoprim.

- Sulfones, sulfonamides or trimethoprim are contraindicated for any reason.

- Volunteers unwilling to comply with study procedures.

- Current suspected or documented ear infection, urinary tract infection, bronchitis,

traveler's diarrhea, Pneumocystis carinii pneumonia, or any other bacterial infection.

- Volunteers with colon resection, gastric bypass, lap band, or any other conditions

inhibiting gastric absorption of drug.

- Current or previous participation within 28 days of enrollment in another research

study that involves the use of medication, contrast, or any other compound that may alter blood count and/or blood chemistry (liver function, kidney function or electrolyte balance), unless waved by PI.

- Donation of 450mL (one unit) of blood or more within 8 weeks (56 days) prior to study

enrollment, unless waved by PI.

- Current use of medications contraindication with sulfamethoxazole/trimethoprim use:

Bepridil, Cisapride, Dofetilide, Levomethadyl, Mesoridazine, Pimozide, Terfenadine, and Thioridazine. Other medications will be screened by study investigators to ensure the safety of research participants and maintain the quality of the study.

Locations and Contacts

University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States
Additional Information

Starting date: July 2010
Last updated: June 9, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017